Legal & General Group
OKUR

Legal & General Group’s OnKure Therapeutics OKUR Stock Holding History

Legal & General Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-142
Closed -$2.35K – 3523
2024
Q1 		$2.35K Hold
142
– – ﹤0.01% 3339
2023
Q4 		$2.27K Buy
142
+28
+25% +$1.75K ﹤0.01% 3363
2023
Q3 		$8.68K Hold
114
– – ﹤0.01% 3294
2023
Q2 		$7.48K Buy
+114
New +$9.18K ﹤0.01% 3348
2022
Q2 		– Sell
-70
Closed -$2K – 3684
2022
Q1 		$2K Hold
70
– – ﹤0.01% 3553
2021
Q4 		$6K Buy
70
+14
+25% +$1.03K ﹤0.01% 3538
2021
Q3 		$4K Sell
56
-15
-21% -$1.27K ﹤0.01% 3489
2021
Q2 		$7K Buy
+71
New +$7.92K ﹤0.01% 3448

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Legal & General Group's OKUR Position: Q2 2024 in Review

Legal & General Group sold out of OnKure Therapeutics (OKUR) in Q2 2024, closing a stake of 142 shares — an estimated $2.35K sold.

Legal & General Group first reported a position in OKUR in Q2 2021 and held it in 8 quarters. The position peaked at $8.68K in Q3 2023. 66 funds tracked by Wall St. Rank hold OKUR as of Q2 2024.

  • Legal & General Group reported no remaining OnKure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 142 OnKure Therapeutics shares in Q2 2024, an estimated $2.35K.
  • Legal & General Group first reported a position in OnKure Therapeutics in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's OnKure Therapeutics position peaked at $8.68K in Q3 2023.
  • 66 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.